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Down to the WIRE: Employee Cannabis Screening in New Jersey
Christina Zarcone
Introduction:
This paper examines employment issues related to the legalization of cannabis in New
Jersey. Now that the state has legalized recreational cannabis, employers must decide how to
implement the new legislation in their places of business. While recreational cannabis use is no
longer illegal, employers are still entitled to maintain safe drug-free work environments. Thus,
employers face challenges pertaining to testing for cannabis use in the workplace as well as taking
adverse actions against employees and potential employees for the use, distribution, possession,
and promotion of cannabis. Due to the lack of concrete guidance from the legalization legislation
and the Cannabis Regulatory Commission (“CRC”), employers should avoid testing employees
for cannabis use and taking adverse actions against employees who test positive for cannabinoid
metabolites because neither drug tests nor physical examinations for impairment are indicative of
an employee being “under the influence” at work.
Part I of this paper provides an overview of New Jersey’s cannabis legalization legislation
itself as it pertains to employers. On February 22, 2021, Governor Murphy signed into law the
New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act
(“NJCREAMMA”), which legalized recreational cannabis in New Jersey. 1 The law regulates
employers’ responsibilities and employees’ rights regarding workplace cannabis use. 2 Under the
law, employers may conduct employee drug screenings but must disregard any positive cannabis
results.3 Employers, however, are not required to ignore positive cannabis results because they are

1

New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act. N.J. Stat. Ann. §
24:6I.
2
N.J. Stat. Ann. § 24:6I-52.
3
Id. § 24:6I-52a(1).
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permitted to enforce a drug-free workplace.4 The law makes clear that an employer may not refuse
to hire or employ an individual who uses cannabis. 5
Employers also are prohibited from taking adverse actions against an applicant or
employee who uses cannabis or solely because the applicant or employee tests positive for
cannabinoid metabolites.6 “Adverse employment actions” include refusing to hire or employ an
individual; barring or discharging an individual from employment; requiring an individual to retire
from employment; or discriminating against an individual in compensation or in any terms,
conditions, or privileges of employment.7 The law also includes employer protections by
recognizing that an employer may maintain a drug- and alcohol - free workplace, is not required
to permit or accommodate the use, consumption, being under the influence, possession, transfer,
display, transportation, sale, or growth of cannabis or cannabis items in the workplace, and may
prohibit employee use of cannabis items or intoxication by employees during work hours and while
driving.8
Part II of this paper discusses when and how employers are permitted to conduct and use
drug testing to maintain a drug free work environment. This section covers the pitfalls of both
aspects of testing for cannabis – scientific lab testing as well as physical impairment examinations
- and discusses why current testing methods are unreliable regarding “real-time” impairment.
NJCREAMMA allows employers to use drug test results to determining appropriate employment
actions only if (1) the drug test includes scientifically reliable testing of blood, urine, or saliva; and
(2) a physical evaluation is performed to determine an employee’s state of impairment. 9

4

Id. § 24:6I-52b(1)(a).
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Part III examines the potential liability employers may face for using the Workplace
Impairment Recognition Experts (“WIREs”), who NJCREAMMA designates as the only
individuals who may conduct the physical evaluations. 10 NJCREAMMA defines WIREs as
individuals certified to ascertain an employee’s state of impairment and trained to detect and
identify an employee’s use or impairment from cannabis or other intoxicating substances. 11
NJCREAMMA requires employers have a good-faith belief that an employee engaged in conduct
prohibited under the law, such as using, being under the influence, possessing, selling, or
transporting cannabis while in the workplace or during work hours, to take adverse actions against
that employee on the basis of a positive cannabis drug test.12 The focus of this section is the
challenge WIREs face in determining whether an employee is under the influence as well as the
vast number of unanswered questions regarding workplace protocols. Significantly, the CRC has
not yet promulgated guidelines explaining how WIREs should judge impairment using a physical
examination.
Part IV of this paper highlights the possible ramifications for employers for testing
employees for impairment and taking subsequent adverse action – namely discrimination suits
because of unlawful discharge. Employers would be wise not to rely on current impairment testing
methods when discharging or taking adverse action against employees because an employer in
violation of the law may be liable for a civil penalty outlined in the decriminalization legislation 13
as well as other discrimination connecting cannabis use to protected groups.
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Id. § 24:6I-52a(2)(a).
Id. § 24:6I-52a(2)(b).
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Part V concludes this paper by summarizes the arguments against taking adverse
employment action as the result of an employee’s positive test result for cannabis. It highlights
the nebulous nature of testing for cannabis impairment as well as potential employer liability.
Part I. New Jersey’s legalization of cannabis consumption leaves a lot of questions
unanswered for employers and employees alike.
A. The New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace
Modernization Act legalizes recreation use of cannabis.
On February 22, 2021, New Jersey Governor Phil Murphy signed into law NJCREAMMA,
which legalized adult recreational use of cannabis for individuals over 21, and a companion bill
that decriminalized the recreational use of cannabis. 14 The new legislation prohibits an employer
from taking adverse action against an individual solely because that person does - or does not - use
marijuana recreationally and, thus, creates a new “protected class” under New Jersey law. 15
Section 52a(1) of NJCREAMMA provides:
No employer shall refuse to hire or employ any person or shall discharge from
employment or take any adverse action against any employee with respect to
compensation, terms, conditions, or other privileges of employment because that
person does or does not smoke, vape, aerosolize or otherwise use cannabis items,
and an employee shall not be subject to any adverse action by an employer solely
due to the presence of cannabinoid metabolites in the employee's bodily fluid from
engaging in conduct permitted under P.L.2021, c.16. 16
Many states, such as Colorado, Iowa, New Mexico, Pennsylvania, and Oklahoma, provide
exemptions from legalization laws for employees with “safety-sensitive” jobs such as those “which
performance by a person under the influence of drugs or alcohol would constitute an immediate or

14

N.J. Stat. Ann. § 24:6I.
Mark Diana & Michael Riccobono, Recreational Marijuana Is Legal in New Jersey: What Employers Need to
Know, OGLETREE DEAKINS, (Feb. 23, 2021), https://ogletree.com/insights/recreational-marijuana-is-legal-in-newjersey-what-employers-need-to-know/.
16
N.J. Stat. Ann. § 24:6I-52a(1).
15
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direct threat of injury or death to that person or another.” 17 Despite lobbying efforts,
NJCREAMMA provides no such exception for employees in safety-sensitive job positions. 18 New
Jersey common law privacy rights have long been interpreted as prohibiting random drug testing
for employees;19 yet, the Supreme Court of New Jersey has also held that persons in safetysensitive job positions are exempted from this prohibition.20 NJCREAMMA, however, does not
include an exception for employees in safety-sensitive positions.21 Consequently, no matter the
safety-sensitive nature of a job, employers must refrain from taking adverse action against
employees for marijuana use outside of work.
B. New Jersey employers have no duty to accommodate cannabis use, possession,
distribution, or promotion in the workplace.
1. No duty to accommodate
Although New Jersey’s cannabis legalization law is progressive, it does not prevent New
Jersey employers from establishing drug- and alcohol-free workplaces. NJCREAMMA makes
clear that employers do not have to permit or accommodate cannabis use in the workplace or during
work hours. Section 52b(1)(a) specifically states that nothing in the law:
Requires an employer to amend or repeal, or affect, restrict or preempt the rights
and obligations of employers to maintain a drug- and alcohol-free workplace or
require an employer to permit or accommodate the use, consumption, being under
the influence, possession, transfer, display, transportation, sale, or growth of
cannabis or cannabis items in the workplace, or to affect the ability of employers to
have policies prohibiting use of cannabis items or intoxication by employees during
work hours.22
17

Lisa Nagele-Piazza, What Is a 'Safety-Sensitive' Job Under State Marijuana Laws?, SHRM (Oct. 5, 2021),
https://www.shrm.org/resourcesandtools/legal-and-compliance/employment-law/pages/what-is-a-safety-sensitivejob-under-state-marijuana-laws.aspx.
18
New Jersey Passes New Law Regulating Employers’ Ability to Test For Marijuana In The Workplace, ARCHER,
(Feb. 2021), https://www.archerlaw.com/new-jersey-passes-new-law-regulating-employers-ability-to-test-formarijuana-in-the-workplace/ (citing N.J. Stat. Ann. § 24:6I).
19
Hennessey v. Coastal Eagle Point Oil Co., 129 N.J. 81 (1992).
20
Id.
21
New Jersey Passes New Law, supra note 18.
22
N.J. Stat. Ann. § 24:6I-52b(1)(a).
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Because federal law continues to classify marijuana as a Schedule I Controlled Dangerous
Substances, employers are permitted to revise their employee prohibitions accordingly.
NJCREAMMA thus creates a carve-out for federal contract employers, providing that:
If any of the provisions set forth in this paragraph or subsection a. of this section
result in a provable adverse impact on an employer subject to the requirements
of a federal contract, then the employer may revise their employee prohibitions
consistent with federal law, rules, and regulations.23
As a result, federal contractor employers remain free to take adverse actions against employees
who test positive for cannabis use and none of the NJCREAMMA provisions apply to those
employees.
2. Employee drug testing under NJCREAMMA
To maintain drug– and alcohol–free work environments, employers may test employees
for cannabis use in six instances including when there is reasonable suspicion of cannabis use at
work, observable signs of intoxication at work, or as part of a work-related accident investigation.
Employers can also test as part of random drug tests, pre-employment screening, or regular
screening of current employees to determine use during work hours. 24 This leaves open a lot of
opportunity for employers to continue to drug test their workforce. The true quagmire for
employers, therefore, is not their ability to drug test, but their inability to do anything with that
information once they have it because the presence of cannabis in an employee’s system is no
longer an adequate reason, standing alone, to take adverse employment action against the
employee.25 This begs the question: why test in the first place?

23

Id. § 24:6I-52b(1)(b).
Id. § 24:6I-52a(1).
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Id.
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NJCREAMMA specifies that a legitimate drug test consists of a two-part test that includes
both “scientifically reliable objective testing methods and procedures, such as testing of blood,
urine, or saliva, and a physical evaluation in order to determine an employee's state of
impairment.26 The law’s new requirement that the employer conduct a physical evaluation is of
note for two reasons: (1) there is currently no reliable method for assessing real-time impairment
for cannabis use and (2) the physical evaluation must be conducted by a certified Workplace
Impairment Recognition Expert. 27 The law describes WIREs as having the ability to “opine on
the employee’s state of impairment, or lack thereof, related to the usage of a cannabis” due to their
requisite certification.28

NJCREAMMA, in turn, delegated to the Cannabis Regulatory

Commission (“CRC”) the responsibility of establishing the certification process for WIREs in
consultation with the Police Training Commission. 29 Conspicuously absent from the law is any
mention of what the certification process will look like, who these WIREs will be – employees or
independent contractors – and what the physical examination will include.
NJCREAMMA, however, does permit a certification from a current drug recognition
program to qualify as WIRE certification. 30 This is troubling because there is currently no physical
examination that allows someone to assess with any degree of certainty whether another person is
suffering from impairment due to cannabis use. 31 So, if an already existing program of certification
for impairment recognition qualifies one to become a WIRE, these so called “experts” will be
woefully unequipped to make determinations on cannabis impairment.

26

Id. (emphasis added).
N.J. Stat. Ann. § 24:6I-52a.
28
Id. § 24:6I-52a(1).
29
Id. § 24:6I-52a(2)(a).
30
Id. § 24:6I-52a(2)(b).
31
See generally Part II.
27
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Another major concern is the law’s vague language stating that employers may not take
adverse action against an individual solely because that person does - or does not - use cannabis
recreationally.32 While on its face this seems like a big win for cannabis users, this statement gives
little indication as to what information employers must have before they are permitted to take
adverse action. This statement could be interpreted to mean that a physical impairment test is
required in addition to cannabis use, but the law does not specifically state such a premise. 33 The
legislation merely states that any drug test must also be accompanied by a physical examination
and that an employer “may use the results of the drug test when determining the appropriate
employment action concerning the employee.” 34 The implication is that an employer does not
need to use a drug test at all to take adverse employment action against an employee regarding
suspected cannabis use.
Furthermore, even where a WIRE determines that an employee is not impaired in the
workplace, nothing in the law prevents an employer from taking adverse action if it has a
“reasonable suspicion” of cannabis use, possession, distribution, or display of cannabis. 35 Yet,
based on the newly protected classification of cannabis users, employers could, simply by
conducting the drug tests, subject themselves to civil liability for discrimination if the primary
reason behind any adverse employment action was a positive drug test result.
Part II. There are currently no testing methods, either laboratory based or physical, which
allow for an accurate indication of real-time impairment due to cannabis consumption

32

N.J. Stat. Ann. § 24:6I-52a(1).
Diana & Riccobono, supra note 15 (citing N.J. Stat. Ann. § 24:6I-52a(1)).
34
Id. § 24:6I-52a(1).
35
Cannabis Regulatory Commission Rules Released: The Thorny Area of Managing Employee Personal Marijuana
Use, KSBRANIGAN (Aug. 26, 2021), https://www.ksbraniganlaw.com/news/2021/8/26/cannabis-regulatorycommission-rules-released-the-thorny-area-of-managing-employee-personal-marijuana-use (citing N.J. Stat. Ann. §
24:6I-52a(1)).
33
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A. Current laboratory-based testing methods for cannabis use urine, blood, or saliva to
determine the presence of cannabinoid metabolites in a person’s system up to 3
months following consumption.
“What you need to remember is it doesn’t matter if it’s urine, oral fluid or hair
testing—it just reflects use. It doesn’t inform you whether someone was impaired
or what their usage patterns are.”36 – Dr. Barry Sample, director of science and
technology for employer solutions at Quest Diagnostics.
Marijuana testing detects evidence of cannabis use but not necessarily impairment.
Cannabis is a plant that produces compounds called cannabinoids, such as tetrahydrocannabinol
(“THC”).37 THC that enters the body is absorbed into the bloodstream, temporarily stored in an
individual’s organs and fatty tissues, and broken down in the liver. 38 Eventually, THC and its
cannabinoid metabolites exit the body in urine and stool. 39
The amount of THC in cannabis determines its strength. The same THC strength, however,
can have very different effects on individual users depending on their weight, the manner of
consumption - smoking versus edibles, - and their frequency of use. 40 Jane Terry, the vice
president of government affairs at the National Safety Council (“NSC”) has stressed that there is
no scientific test for real-time cannabis impairment and that:
[p]olicymakers and others think that because we can test for alcohol, it can
be done for cannabis. But cannabis goes to your fat cells. Presence does not
mean impairment—it can stick around for days or weeks. But because you
can’t test impairment, it is really challenging for employers to figure out
how to react if someone is using on the job.41

36

Nagele-Piazza, supra note 17.
Marijuana (THC) Testing, TESTING.COM, https://www.testing.com/tests/marijuana-thc-testing/ (last visited
Apr. 7, 2022).
38
How Long Does Weed (Marijuana) Stay in Your System?, HEALTHLINE,
https://www.healthline.com/health/how-long-does-weed-stay-in-your-system#metabolization-time (last visited
Apr. 7, 2022).
39
How Long, supra note 38.
40
Nagele-Piazza, supra note 17.
41
Nagele-Piazza, supra note 17.
37
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With this concept in mind, employers should be extra careful regarding how much reliance they
place in the results of cannabis drug tests when looking for evidence of impairment.
The most popular drug test for cannabis use is a urine analysis. Cannabis is detectable in
urine for a significant range of time following an individual’s last use depending on how often that
individual uses cannabis.42 While cannabis shows up in an occasional (up to three times a week)
users’ urine for approximately 3 days, a chronic heavy user (multiple times a day) can have a
positive urine test for up to 30 days.43 Similar results are found when testing for the presence of
cannabis in an individual’s blood, saliva, and hair with ranges from 1 day in the cases of blood and
saliva, up to 90 days in the case of hair follicle testing.44
The bottom line is that lab testing is an incredibly inaccurate way to measure a person’s
current level of impairment due to cannabis use. While most short-term effects of impairment
begin to taper off approximately 1-3 hours after consumption, an individual can test positive for
cannabis use up to 3 months after consumption.45 Considering this large discrepancy, it is no
wonder New Jersey’s legislation demands a second test for impairment; however, the inaccuracy
of those physical tests provides little to no employment protection for cannabis users. After all,
employers only need a good-faith belief that an employee engaged in some other prohibited
conduct such as being under the influence of cannabis at work in addition to the positive test
result.46 NJCREAMMA does not elaborate on what qualifies as a “reasonable” or “good-faith”
belief.

42

How Long, supra note 38.
Id.
44
Id.
45
Id.
46
Cannabis Regulatory Commission, supra note 35.
43
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B. Physical impairment testing for cannabis use relies on methods of observing
symptoms of alcohol and other-drug impairment which are not applicable or
conclusive when it comes to cannabis-based impairment.
Unlike alcohol drug tests, there exist no scientifically accepted drug tests for cannabis that
can detect real-time impairment. This is more than likely the reason behind the lack of guidance
in the CRC’s initial rules regarding the WIRE certification process and physical testing
requirements.47 New Jersey relies on observable physical symptoms in order to diagnose druginduced impairment for a multitude of drugs. 48 These observable physical symptoms include
nystagmus (jerky movement of eye when moved horizontally or vertically), eye focus and
convergence (or lack of), pupil size, pupil reaction to light, vital signs (pulse/respirations), body
temperature, muscle tone/movement, speech, gait, time and distance perception, alteration in
thought formation, body tremors, bloodshot eyes, disorientation, drowsiness, impaired memory,
increased appetite, lack of concentration, mood changes, odor of cannabis, and relaxed
inhibitions.49 Looking at this list, it would appear that there are plenty of physical signs for WIREs
to observe when conducting a physical exam for cannabis use; but looks can be deceiving.
Most of these physical signs of impairment are not actually indicative of cannabis
impairment.50 Cannabis use and impairment has no physical effect on nystagmus, pupil size, pupil
reaction to light, body temperature, and muscle tone,51 thus, observations of those symptoms would
not provide WIREs with any indicia whatsoever of cannabis impairment. The only consistently
reliable, observable physical signs of cannabis impairment are an elevated pulse rate and increased

47

N.J.A.C. 17:30.
Indicators Consistent Drug Categories Matrix 2018, NJ.GOV,
https://www.state.nj.us/lps/njsp//////division/investigations/pdf/adtu/Indicators_Consistent_Drug_Categories_M
atrix_2018.pdf (last visited Apr. 7, 2022).
49
Id.
50
Id.
51
Id.
48
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blood pressure.52 However, anyone who has ever been forced to take a field-sobriety test will tell
you that nerves and test anxiety alone can trigger those observable signs of “impairment” in an
unimpaired person, and experts in the area of field sobriety testing agree. 53 According to the Field
Sobriety Testing Resource, “[fo]r many people, being stopped by the police and ordered to perform
a number of unfamiliar physical tasks is intimidating and could result in a failing score.” 54
The other “general indicators” outlined by New Jersey are also riddled with issues because
they either can result from a number of factors beyond cannabis impairment or are simply too
difficult for a WIRE to assess. Body tremors, for example, can be caused by nerves. 55 Bloodshot
eyes could be caused by lack of sleep, allergies, or crying.56 Drowsiness or lack of concentration
could be caused by lack of sleep or depression57, and odor of cannabis could be caused by being
in the vicinity of someone else smoking cannabis. Finally, it would be interesting indeed to see
how a WIRE might go about accurately identifying an employee’s alteration in thought formation,
increased appetite, mood changes, or relaxed inhibitions. In sum, it is not difficult to understand
why no viable test has emerged in this field and why the CRC is currently stalled in its attempt to
identify one.
New methods for testing physical impairment have emerged but are still a long way away
from perfection. The Druid App, for example, can test for current impairment from cannabis

52

Id.
Health or Mental Problems and Field Sobriety Tests, FIELDSOBRIETYTESTS.ORG,
http://www.fieldsobrietytests.org/healthormentalproblemsandfieldsobrietytests.html (last visited Apr. 7, 2022).
54
Health or Mental Problems, supra note 53.
55
Anxiety Tremors: What Causes It?, HEALTHLINE, https://www.healthline.com/health/anxiety-shaking#overview
(last visited April 29, 2022).
56
Kristin Canning, 8 Reasons Your Eyes are Red, HEALTH, (Nov. 3, 2017), https://www.health.com/condition/eyehealth/red-eyes-bloodshot.
57
Fatigue and Depression: Are they Connected?, HEALTHLINE,
https://www.healthline.com/health/depression/fatigue (last visited April 29, 2022).
53
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through an app on an individual’s phone.58 A user starts by doing several tests on the app while
they are sober to set a standard baseline for sobriety. 59 After this baseline is set, a user can utilize
the app to assess whether they are impaired; meeting that baseline standard would indicate the user
is not impaired.60 The test is simple: an individual follows a dot with their finger on a screen and
it “assesses” the user’s level of impairment. 61 While this system seems promising, obvious issues
remain. Just as with other forced sobriety tests, anxiety can affect a person’s motor skills. The
developers of the Druid App have not run tests to account for this variable. 62 Even more
problematic is the fact that the developers say failing to meet the baseline test could merely indicate
that the individual did not sleep properly the night before. 63
The most promising physical test for impairment is a light-based imaging test developed
by researchers at Massachusetts General Hospital (“MGH”). 64 This scientific breakthrough comes
amid the debate in the Commonwealth over how to police cannabis-impaired driving in the wake
of legalization, which is a significant concern for New Jersey as well. 65 Based on the presumption
that existing impairment tests are flawed, the scientists at MGH felt that reliance on outdated tests
for alcohol impairment should be eschewed for a more reliable brain-based test. 66 “For so long,
our model has been alcohol, so there’s been a lot of focus on breath and blood levels,” Dr. Jodi

58

Michael Milburn & William DeJong, A paradigm shift in impairment testing for cannabis: The DRUID® App,
HEALTH EUROPA (Feb. 7, 2020), https://www.healtheuropa.com/a-paradigm-shift-in-impairment-testing-forcannabis-the-druid-app/94154/.
59
Id.
60
Id.
61
Id.
62
Id.
63
Milburn &DeJong, supra note 58.
64
Dan Adams, MGH Claims Breakthrough in Detecting Marijuana Impairment, BOSTON GLOBE (Feb. 4, 2022),
https://www.bostonglobe.com/2022/02/04/marijuana/mgh-claims-breakthrough-detecting-marijuana-impairment/.
65
Id.
66
Id.
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Gilman, who led the research, said. “Our thought was, ‘What about looking directly at the
brain?’”67
After testing 169 volunteers, the MGH study found that people classified as “impaired”
had significantly higher levels of oxygenated hemoglobin than subjects who took a placebo or did
not get too high from the THC-infused edible. 68 The researchers performed the test by using
functional near-infrared spectroscopy, or fNIRS, to measure the photon reflections from lowpower LED bulbs mounted on a portable skullcap and shined into the skulls of the subjects. This
type of technology is already widely used in smartwatches and other gadgets to measure a person’s
heart rates and blood oxygenation.69 The MGH tests are promising because they yielded false
positives in just 10 percent of subjects and rarely indicated impairment in subjects who consumed
THC-infused edibles yet were not deemed functionally impaired. 70 Imagine a similar situation in
which a person consumes a glass of alcohol yet remains sober enough to drive.
The MGH study has profound implications for both cannabis impairment testing and
NJCREAMMA’s WIRES. MGH conducted tests using drug recognition experts to assess
impairment in the same 169 individuals and found that those tests produced false positives in a
staggering 34 percent of the subjects who were not deemed impaired by the fNIRS test or the
subjects’ self-assessments.71 After finding that the drug recognition experts incorrectly flagged 20
percent of the volunteers who had eaten the placebo and were verifiably sober, the MGH scientists
discarded drug recognition protocol as an accurate reference for impairment. 72 So, while it is easy

67

Id.
Id.
69
Adams, supra note 64.
70
Id.
71
Id.
72
Adams, supra note 64.
68
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to suggest that employers should wait for the CRC to issue its rules for WIREs and their
certification before taking adverse employment action against cannabis users, given the current
data, it would be far safer for employers to steer clear of physical impairment testing altogether
until an accurate method is developed.
Part III: The lack of information concerning requirements for WIREs under NJCREAMMA
should steer employers away from using them in the workplace.
A. Employers should not conduct any drug testing for cannabis impairment because the
CRC failed to issue rules regarding WIREs and have thus exempted employers from
conducting physical examinations for impairment.
As discussed in Part I, NJCREAMMA provided little guidance as to how WIREs ought to
be certified or conduct physical impairment tests for cannabis use. 73 The law merely states that
WIREs are individuals who have completed a Drug Recognition Expert program provided by a
Police Training Commission approved school, received a Workplace Impairment Recognition
Expert certification, and are either employed by or a contractor of an employer. 74
Because there were no standards regarding the physical prong of the drug testing
requirement or its administers, NJCREAMMA provisions impacting workplaces were not
immediately operative in February 2021.75

The employment protections and drug testing

requirements outlined in Section 52 of the Act were to go into effect once the CRC promulgated
its initial rules and regulations.76 As noted above, the law specifically tasked the CRC with
clarifying restrictions on employers regarding workplace drug testing and any adverse employment
actions taken in response to said testing.77

73

See generally Part I.
N.J. Stat. Ann. § 24:6I-52a(2).
75
Cannabis Regulatory Commission, supra note 35.
76
Id. (citing N.J. Stat. Ann. § 24:6I).
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N.J. Stat. Ann. § 24:6I-52.
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The CRC issued its initial rules on August 19, 2021, thus making Section 52 of
NJCREAMMA operative against employers. 78 Those initial rules, however, do not sufficiently
address workplace testing. In addition, the CRC has indefinitely postponed the requirement of a
physical evaluation by a WIRE until standards are developed. The initial rules provide that:
Notwithstanding the provisions of N.J.S.A. 24:6I-52, until such time that the
Commission, in consultation with the Police Training Commission established
pursuant to N.J.S.A. 52:17B-70, develops standards for a Workplace Impairment
Recognition Expert certification, no physical evaluation of an employee being drug
tested in accordance with N.J.S.A. 24:6I-52 shall be required. 79
This lack of guidance poses obvious yet challenging questions to employers seeking to
ensure drug-free work environments. Precisely how does drug testing help employers accomplish
that goal at all? If a physical exam is not only not required but not recommended by the CRC,
what will qualify as an adequate reason for taking adverse employment action against an employee
for cannabis impairment aside from a positive drug test result? Without the ability to test an
employee for current impairment through a physical test, an employer would have to rely on having
a “reasonable suspicion” of impairment.80 This vague directive should be troubling to employers
and should constitute a red flag to stay away from testing altogether. It opens the door for
employees who receive positive drug test results to claim that their employers took adverse action
solely based on the test, which NJCREAMMA expressly prohibits. 81
A recent case in Arizona is illustrative. There, a Walmart employee took a drug test after
an on-the-job injury and tested positive for cannabis.82 Walmart administered that drug test two

78

N.J.A.C. 17:30.
Id. (emphasis added).
80
N.J. Stat. Ann. § 24:6I-52a(1).
81
See Robert Kline, Courts Are Siding with Employees Who Use Medical Marijuana, NAT’L L. REV. (June 19,
2019), https://www.natlawreview.com/article/courts-are-siding-employees-who-use-medical-marijuana.
82
Whitmire v. Wal-Mart Stores, Inc., 359 F. Supp. 3d 761, 769 (D. Ariz. 2019).
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days after the injury and the test only indicated cannabis use, not cannabis impairment. Walmart
fired the employee anyway on the theory that the test result indicated she was impaired when she
was injured during her shift.83 The employee subsequently sued Walmart for wrongful termination
in violation of the Arizona Medical Marijuana Act and succeeded on that claim. 84 New Jersey
employers should see this as a cautionary tale against testing employees for cannabis impairment
because while nothing in the law requires employers to drug test employees before taking adverse
action, NJCREAMMA does imposes significant requirements on employers if they do conduct
such drug testing.85
B. There are too many crucial yet unanswered questions concerning WIREs for
employers to feel comfortable using them to test employees for cannabis
impairment.
Employers should be cognizant of the myriad unanswered questions concerning WIREs
that could cause general disruption in the workplace as well as subject them to civil liability. First
and foremost, at what stage in the drug-testing process does the WIRE get involved? Pre-testing?
Post-testing? Must the expert first “approve” the drug testing a particular employee? It is easy to
see how these unanswered questions could leave an employer open to liability. If a WIRE becomes
involved after a positive test result, an employee could make a claim that any subsequent positive
physical impairment assessment was a biased result due to the WIRE’s knowledge that the
employee uses cannabis, which would violate the statute. 86 If a pre-employment drug test is
required by the employer and those who test positive experience an increased frequency of physical
testing, other the other hand, that practice could be construed as targeting the newly protected class
of cannabis users in New Jersey.
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The nature and extent of the WIREs influence over the employer’s determination is also
unclear. Does the WIRE merely assess the employee’s level of impairment at the time in question
for the employer’s consideration among other factors or is the WIRE’s opinion binding on the
employer?87 Given that WIREs may themselves be employees, the scope of their role and authority
has considerable implications for the workplace climate. Finally, how might this process work
with employees who work remotely? Will employers use WIRE services remotely via video?
Given these open questions, there is only one reasonable course of action for employers: they ought
to steer clear of testing employees for cannabis use. Consumption of and impairment from alcohol
has historically been prohibited in New Jersey workplaces without the need to implement such
convoluted measures for testing impairment.88 Employers should follow the same protocol for
cannabis as they do for alcohol and, thereby mitigate the liability risks that attend to cannabis
testing under NJCREAMMA.
Part IV: Employers should avoid testing employees for cannabis in light of current litigation
involving NJCREAMMA and unreliable testing methods.
Another reason to avoid testing is that employers who violate NJCREAMMA face civil
penalties in amounts up to $1,000 for the first violation, $5,000 for the second violation, and
$10,000 for each subsequent violation.89 Moreover and while there is no private right of action
against an employer under the NJCREAMMA,90 employees subjected to adverse employment
actions for off-duty marijuana are likely to pursue claims of discrimination under a public policy
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cause of action.91 Thus, while the sole remedy under NJCREAMMA for employers may be small
fines, there is the potential for settlement windfalls in successful discrimination cases.
Current litigation indicates how fraught workplace drug testing is for employers under
NJCREAMMA. Amazon is defending a lawsuit in which the plaintiffs allege that the company
violated NJCREAMMA, New Jersey common law, and New Jersey public policy by refusing to
hire applicants and wrongfully discharging employees based on positive drug test results between
February 22, 2021 and June 1, 2021.92 On June 1, 2021, Amazon changed its drug testing policy
to no longer disqualify applicants or terminate current employees for positive cannabis tests but
the ongoing lawsuit seeks back pay, front pay and punitive damages for the period prior to those
policy amendments.93
In Hunt v. Matthews International Corp., the plaintiff alleged that their employer refused
to hire them after a pre-employment drug screen returned a positive cannabis result. Mr. Hunt
claims that after allegedly making no effort to speak with him, his employer withdrew an offer of
employment in violation of New Jersey’s anti-discrimination laws. 94 Significantly, Mr. Hunt
claims that he disclosed his status as a cannabis user before the test and made multiple attempts to
discuss the issue with his potential employer, yet he was still denied employment. 95 This case
highlights how the competing interests of employee cannabis users and employers attempting to
maintain a drug free work environment will likely play out in the courts as discrimination suits. .
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It is also important to note that drug recognition expert (“DRE”) testing may go the way of
the dodo in New Jersey following the decision of a designated Special Master to determine whether
DRE testing is scientifically reliable in State v. Michael Olenowski.96

Defendant Michael

Olenowski was convicted of Driving While Intoxicated (DWI) under N.J.S.A. 39:4-50. 97 At his
trial, the prosecutor introduced a police expert used to detect drug influence as evidence, known
as DRE. The defendant argued that the DRE evidence was scientifically insufficient to be held
reliable and valid.98 On appeal, the New Jersey Supreme remanded the matter to a Special Master
to decide whether DRE evidence is generally accepted in the scientific community and therefore
satisfies the expert evidence standard demanded by the New Jersey Rules of Evidence. 99
Olenowski could have a significant impact on the implementation of NJCREAMMA. If
the Special Master determines that DRE testimony is not sufficiently based in scientific evidence
and the New Jersey Supreme Court affirms, what will become of NJCREAMMA’s two prong drug
test and WIREs? Without a physical examination, what will formulate the basis of an employer’s
decision to take adverse action against an employee who is allegedly impaired at work? Olenowski
ought to further encourage employers to avoid drug testing employees for cannabis use in the
workplace as it may quickly become obsolete.
Part V: Conclusion
New Jersey’s legalization of cannabis consumption leaves a lot of questions unanswered
for employers and employees. There are currently no testing methods, either laboratory based or
physical, which allow for an accurate indication of real-time impairment due to cannabis
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consumption. The additional lack of information concerning requirements for WIREs under
NJCREAMMA should steer employers away from using them as things currently stand. The flurry
of litigation surrounding employee drug testing attests to the fact that employers would be opening
themselves up to litigation if they follow suit.

Given the considerable legal uncertainly

surrounding cannabis drug testing in the workplace, New Jersey employers would wise to simply
continue do what they have always done: make adverse employment actions based on an
employee’s actual work performance.
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